EU-Prolia®

DRUG2 trials

Sponsors

Shanghai Henlius Biotech, Xentria, Inc.

Conditions

Healthy Male VolunteersHealthy Participants

Phase 1

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects

CompletedNCT04534582

Shanghai Henlius BiotechHealthy Male Volunteers

Start: 2020-11-03End: 2023-09-12Updated: 2025-01-20

Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®

CompletedNCT06310824

Xentria, Inc.Healthy Participants

Start: 2024-06-05End: 2025-07-22Updated: 2025-07-29